Tuberculosis Elimination at Stake
|
By LabMedica International staff writers Posted on 26 Apr 2016 |

Image: A map showing tuberculosis cases in Europe from 2014 (Photo courtesy of European Centre for Disease Prevention & Control).
Ahead of World TB Day, a new guidance paper and surveillance report on tuberculosis (TB) in Europe urge for immediate diagnostic screening and care of the most vulnerable populations, including refugees and migrants, and the poor and marginalized.
Data released in a new report by European Center for Disease Prevention and Control (ECDC; Stockholm, Sweden) and World Health Organization (WHO) show that an estimated 340,000 Europeans developed TB in 2014, corresponding to a rate of 3.7 cases per 1 million population. With new TB cases decreasing by 4.3% on average between 2010 and 2014, the WHO European Region has met the Millennium Development Goal target of reversing the incidence of TB by 2015. However, high rates of multidrug-resistant (MDR) TB and TB affecting vulnerable populations (e.g., homeless, drug and alcohol abusers, and migrants from countries with high rates of TB) continue to challenge TB elimination (defined as < 1 case TB disease per 1 million population per year).
The WHO European Region comprises 53 countries with a population of nearly 900 million people, of which around 508 million live in the EU/EEA (European Union/European Economic Area: 28 EU Member States plus Iceland, Liechtenstein, and Norway).
"One quarter of all 480,000 patients sick with MDR TB globally were in the European Region in 2014. This alarmingly high number is a major challenge for TB control", said Dr. Zsuzsanna Jakab, WHO Regional Director for Europe, "The most vulnerable groups [...] are at greater risk of developing MDR TB. Because of their living conditions, TB is often diagnosed late, and it is harder for them to complete a treatment course. If we really want to eliminate TB from Europe, no one must be left behind."
"Social circumstances or lifestyles may make it more difficult for some people to recognize the symptoms of TB, access healthcare services, follow a treatment, or attend regular healthcare appointments. We need to think about tailored interventions for such vulnerable people, which can include outreach teams or directly observed treatment," said ECDC acting director Dr Andrea Ammon, “If TB is not successfully tackled in vulnerable groups, it will not be eliminated."
There is no systematic association between migration and transmission of tuberculosis. The risk of being infected or developing TB disease depends on several factors including TB rates in country of origin. New TB cases in some origin countries (e.g., Syria) are lower than the European Region average. In addition, as TB is not easily transmissible and contacts are limited, there is a low risk that migrants transmit the disease to the resident population.
Universal health coverage should be ensured for refugees and migrants, both documented and undocumented. The European Region is the only one in the world with a consensus document on the minimum package of cross-border TB control and care interventions, including access to medical services irrespective of a migrant's registration status. TB screening must never be used as a reason to reject a refugee or a migrant. The recently published Systematic screening for active tuberculosis: an operational guide provides guidance on how to target and tailor TB screening to detect active disease and provide immediate treatment in populations most at risk.
Related Links:
European Center for Disease Prevention and Control
Data released in a new report by European Center for Disease Prevention and Control (ECDC; Stockholm, Sweden) and World Health Organization (WHO) show that an estimated 340,000 Europeans developed TB in 2014, corresponding to a rate of 3.7 cases per 1 million population. With new TB cases decreasing by 4.3% on average between 2010 and 2014, the WHO European Region has met the Millennium Development Goal target of reversing the incidence of TB by 2015. However, high rates of multidrug-resistant (MDR) TB and TB affecting vulnerable populations (e.g., homeless, drug and alcohol abusers, and migrants from countries with high rates of TB) continue to challenge TB elimination (defined as < 1 case TB disease per 1 million population per year).
The WHO European Region comprises 53 countries with a population of nearly 900 million people, of which around 508 million live in the EU/EEA (European Union/European Economic Area: 28 EU Member States plus Iceland, Liechtenstein, and Norway).
"One quarter of all 480,000 patients sick with MDR TB globally were in the European Region in 2014. This alarmingly high number is a major challenge for TB control", said Dr. Zsuzsanna Jakab, WHO Regional Director for Europe, "The most vulnerable groups [...] are at greater risk of developing MDR TB. Because of their living conditions, TB is often diagnosed late, and it is harder for them to complete a treatment course. If we really want to eliminate TB from Europe, no one must be left behind."
"Social circumstances or lifestyles may make it more difficult for some people to recognize the symptoms of TB, access healthcare services, follow a treatment, or attend regular healthcare appointments. We need to think about tailored interventions for such vulnerable people, which can include outreach teams or directly observed treatment," said ECDC acting director Dr Andrea Ammon, “If TB is not successfully tackled in vulnerable groups, it will not be eliminated."
There is no systematic association between migration and transmission of tuberculosis. The risk of being infected or developing TB disease depends on several factors including TB rates in country of origin. New TB cases in some origin countries (e.g., Syria) are lower than the European Region average. In addition, as TB is not easily transmissible and contacts are limited, there is a low risk that migrants transmit the disease to the resident population.
Universal health coverage should be ensured for refugees and migrants, both documented and undocumented. The European Region is the only one in the world with a consensus document on the minimum package of cross-border TB control and care interventions, including access to medical services irrespective of a migrant's registration status. TB screening must never be used as a reason to reject a refugee or a migrant. The recently published Systematic screening for active tuberculosis: an operational guide provides guidance on how to target and tailor TB screening to detect active disease and provide immediate treatment in populations most at risk.
Related Links:
European Center for Disease Prevention and Control
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







